Filing Flows › Sanara MedTech (SMTI) › Q4 2025
Sanara MedTech (SMTI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 24, 2026
Sanara MedTech (SMTI) reported revenue of $27.5M for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +5% from the quarter before. Operating margin was 3.8%, net loss $1.6M (5.8% of revenue).
Sanara MedTech, Q4 2025: revenue $27.5M (+5% year over year), operating margin 3.8%, net loss $1.6M, operating cash flow $3.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $27.5M | +5% | +5% |
| Operating profit | $1.1M | -64% | — |
| Net earnings | −$1.6M | — | — |
| Operating cash flow | $3.9M | +81% | +323% |
| Free cash flow | $3.9M | +246% | +349% |
What changed
Revenue was $27.5M in Q4 2025, up 5% year over year and up 5% from the previous quarter. Soft Tissue Repair Products was the largest line at 90% of revenue.
Gross margin was 93.2%, up 1.7 points from Q4 2024. Operating profit was $1.1M, a 3.8% margin (down 4.8 points year over year). Operating profit fell $1.2M even though revenue rose $1.2M versus Q4 2024, so costs grew faster than sales. Operating expenses grew 13% against revenue growth of 5%. The fastest-growing cost line was Other operating costs (+263%). The quarter ended with a net loss of $1.6M, narrower than the previous quarter's $30.4M loss. Net interest and other expense of $2.7M was the main reason.
Operating cash flow was $3.9M (up 323% year over year). Non-cash charges added back $668K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $82K left free cash flow of $3.9M.
Questions
What was Sanara MedTech's revenue in the fourth quarter 2025?
Sanara MedTech (SMTI) reported revenue of $27.5M for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +5% from the quarter before.
Was Sanara MedTech profitable in the fourth quarter 2025?
Operating profit was $1.1M (3.8% of revenue) and net loss $1.6M.
Source: Sanara MedTech 10-K on SEC EDGAR.